<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0013985" disease_type="Mental or Behavioral Dysfunction" abbrv="">Emotional disturbances</z:e>, such as <z:hpo ids='HP_0000745'>lack of motivation</z:hpo> or <z:hpo ids='HP_0000716'>depression</z:hpo>, are common after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The drugs mainly used to treat these syndromes in Japan are the cerebral metabolic enhancers whose biochemical and pharmacological profiles are similar to those of <z:chebi fb="0" ids="35469">antidepressant drugs</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>In order to examine the possible therapeutic effect of T-794 [(5R)-3-(6-(cyclopropylmethoxy) 2-<z:chebi fb="0" ids="51140">naphthalenyl</z:chebi>)-5-(methoxymethyl) 2-oxazolidone], a new reversible inhibitor of <z:chebi fb="3" ids="25375">monoamine</z:chebi> oxidase (MAO) type A, on those <z:e sem="disease" ids="C0013985" disease_type="Mental or Behavioral Dysfunction" abbrv="">emotional disturbances</z:e>, its antidepressant activity was compared with those of major cerebral metabolic enhancers in rodents with or without treatment of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Oral administration of T-794 potently prevented <z:chebi fb="0" ids="28487">reserpine</z:chebi>-induced <z:hpo ids='HP_0000508'>ptosis</z:hpo> (ED50 = 4.41 mg/kg), <z:hpo ids='HP_0002304'>akinesia</z:hpo> (ED50 = 3.29 mg/kg), and <z:hpo ids='HP_0002045'>hypothermia</z:hpo> (minimum effective dose = 3 mg/kg) in mice </plain></SENT>
<SENT sid="4" pm="."><plain>It was at least 3.7, 13.0, and 3.3 times more potent than cerebral metabolic enhancers tested (indeloxazine, bifemelane, <z:chebi fb="0" ids="2618">amantadine</z:chebi> and idebenone) in antagonism of the <z:hpo ids='HP_0000508'>ptosis</z:hpo>, the <z:hpo ids='HP_0002304'>akinesia</z:hpo>, and the <z:hpo ids='HP_0002045'>hypothermia</z:hpo>, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Effect of T-794 was also examined in the <z:mp ids='MP_0002573'>behavioral despair</z:mp> test in rats subjected to forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was induced by a combination of bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> (15 min) and systemic <z:hpo ids='HP_0002615'>hypotension</z:hpo> (<z:chebi fb="0" ids="29321">sodium nitroprusside</z:chebi> 5 mg/kg, s.c) </plain></SENT>
<SENT sid="7" pm="."><plain>From 13 d after the surgery, drugs were orally administered twice daily 7 times, and following the last administration rats were assessed for their behavior </plain></SENT>
<SENT sid="8" pm="."><plain>T-794 reduced the duration of immobility in the <z:mp ids='MP_0002573'>behavioral despair</z:mp> test at 30 mg/kg without affecting spontaneous motor activity, whereas indeloxazine showed no significant effect </plain></SENT>
<SENT sid="9" pm="."><plain>Antidepressant-like activity of T-794 was suggested in rodents with as well as those without <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>The results suggest that T-794 may make an important contribution to the treatment of <z:e sem="disease" ids="C0013985" disease_type="Mental or Behavioral Dysfunction" abbrv="">emotional disturbances</z:e> following <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>